Zacks Research Issues Pessimistic Estimate for BHC Earnings

Bausch Health Cos Inc. (NYSE:BHC) – Stock analysts at Zacks Research cut their Q1 2027 earnings estimates for shares of Bausch Health Cos in a research note issued to investors on Friday, July 24th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.80 for the quarter, down from their prior estimate of $0.82. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.05 per share. Zacks Research also issued estimates for Bausch Health Cos’ FY2027 earnings at $3.62 EPS, Q1 2028 earnings at $0.58 EPS and FY2028 earnings at $3.08 EPS.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.78 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.03). Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.37 billion.

BHC has been the subject of a number of other research reports. Royal Bank Of Canada lowered their target price on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a report on Monday, April 27th. Weiss Ratings downgraded Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 4th. Finally, Jefferies Financial Group raised Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Bausch Health Cos presently has a consensus rating of “Reduce” and an average target price of $8.00.

Bausch Health Cos Stock Performance

Shares of BHC stock opened at $4.53 on Monday. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of -1.40 and a beta of 0.42. The company’s 50 day moving average is $4.97 and its 200 day moving average is $5.49. The company has a quick ratio of 0.97, a current ratio of 1.32 and a debt-to-equity ratio of 54.68. Bausch Health Cos has a 52-week low of $4.33 and a 52-week high of $8.69.

Institutional Investors Weigh In On Bausch Health Cos

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Caption Management LLC grew its holdings in Bausch Health Cos by 101.1% in the fourth quarter. Caption Management LLC now owns 4,464 shares of the company’s stock worth $31,000 after purchasing an additional 405,789 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Bausch Health Cos by 12,589.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock valued at $34,000 after purchasing an additional 4,910 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Bausch Health Cos by 6,661.2% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after purchasing an additional 5,329 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Bausch Health Cos by 65.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after purchasing an additional 3,106 shares in the last quarter. Finally, Camelot Portfolios LLC purchased a new position in Bausch Health Cos during the 4th quarter worth $59,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Insider Buying and Selling at Bausch Health Cos

In other news, Director Frank D. Lee sold 24,456 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total value of $132,796.08. Following the sale, the director directly owned 49,339 shares in the company, valued at approximately $267,910.77. This trade represents a 33.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.67% of the company’s stock.

Key Headlines Impacting Bausch Health Cos

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Bausch Health is expected to report earnings on Wednesday, providing a near-term catalyst and an opportunity for management to address operating performance, debt and forward guidance. Bausch Health Cos Expected to Post Earnings on Wednesday
• Neutral Sentiment: The current-year analyst consensus remains $4.05 in earnings per share, although this estimate was not changed in the latest research updates.
• Negative Sentiment: Zacks Research lowered its EPS forecasts across multiple future periods: Q2 2027 to $0.81 from $0.82, Q3 2027 to $1.04 from $1.05, Q4 2027 to $0.93 from $0.95, and full-year 2027 to $3.59 from $3.62. The firm also reduced Q1 2028 to $0.57 from $0.58, Q2 2028 to $0.81 from $0.82, and full-year 2028 to $3.02 from $3.08.
• Negative Sentiment: Zacks maintains a “Strong Sell” rating on BHC. The repeated downward revisions signal weaker expected earnings momentum and add pressure to a stock already trading near its 12-month low and below its 50-day and 200-day moving averages.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.